ASK REDCHAT ANYTHING ABOUT NURIX THERAPEUTICS, INC.
Nurix Therapeutics, Inc. (NASDAQ: NRIX)
Listen to this Section
$15.61
+0.1290
(
+0.83% )
905.1K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| NX-2127 (BTK degrader)DetailsNon-Hodgkin lymphoma, Blood cancer, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Mantle cell lymphoma, Diffuse large B cell lymphoma |
Phase 1 |
| NX-5948DetailsCancer, B-cell malignancies |
Phase 1 |
| NX-1607DetailsSolid tumor/s, Cancer |
Phase 1 |
| NX-5948DetailsWaldenstrom macroglobulinemia |
Phase 1 |
| NX-1607 + paclitaxelDetailsSolid tumor/s, Cancer |
Phase 1a |
| DeTIL-0255DetailsOvarian cancer, Cancer, Cervical cancer, Endometrial cancer |
Failed |
Market Data
|
| Open |
$15.61 |
| Previous Close |
$15.48 |
| Volume |
905.1K |
| Market Cap |
$1.60B |
| Day Range |
$15.30 - $16.27 |
| 52 Week Range |
$8.20 - $22.50 |
| Shares Outstanding |
103.41M |
| Change % |
+0.83% |
| Net Change |
▲ 0.1290 |
| Insider Ownership |
-0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Year | 2020 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-177,701.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-08-01 |
Sale |
-5760.00 |
Ring Christine |
| 2024-08-01 |
Sale |
-3377.00 |
van Houte Hans |
| 2024-07-30 |
Sale |
-1924.00 |
Ring Christine |
| 2024-07-30 |
Sale |
-2886.00 |
van Houte Hans |
| 2024-07-30 |
Sale |
-3207.00 |
Hansen Gwenn |
| 2024-07-18 |
Sale |
-54027.00 |
Kunkel Lori Anne |
| 2024-07-01 |
Sale |
-5760.00 |
Ring Christine |
| 2024-06-20 |
Sale |
-20000.00 |
van Houte Hans |
| 2024-06-13 |
Sale |
-1864.00 |
Ring Christine |
| 2024-06-12 |
Sale |
-1900.00 |
Ring Christine |